Recent Activity

Loading...

MRSN

Mersana Therapeutics, Inc. · NASDAQ

Performance

+10.75%

1W

-27.39%

1M

-28.16%

3M

+77.27%

6M

+17.67%

YTD

-64.77%

1Y

Profile

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc. and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Investment Analysis Report: MRSN

Overview:

MRSN is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $458.21 million. In this report, we will conduct a comprehensive analysis of MRSN's financial health, valuation, earnings and revenue growth, profitability,...

See more ...

Technical Analysis of MRSN 2024-05-10

Overview:

In analyzing the technical indicators for MRSN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key factors, we aim to offer valuable insights and predictions for investors lookin...

See more ...

Recent News & Updates